NYSE American - Delayed Quote USD

Serina Therapeutics, Inc. (SER)

6.00

+0.07

+(1.27%)

At close: June 13 at 3:57:03 PM EDT

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise valuesRecognize the patterns that can lead to strong investment returnsMeet with Serina’s CEO Steven A. LedgerRegister at Smartest-Bet.TribePublic.com HUNTSVILLE, AL, June 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company

GlobeNewswire 6 days ago

SER
+1.27%
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than thre

GlobeNewswire 24 days ago

SER
+1.27%
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina’s common stock to two new non-executive employees on March 20, 2025 (each, an “Option Grant”). Each Option Gra

GlobeNewswire last month

SER
+1.27%
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization

GlobeNewswire last month

SER
+1.27%
Serina Therapeutics to Present at JonesResearch Virtual CNS Day

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT. A live webcast of the fireside chat style presentation will be accessible to registered attendees via the following link: https://u

GlobeNewswire last month

SER
+1.27%
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG Dilemma – A Solution," will take place on Tuesday, April 15, at 9:30 AM ET

GlobeNewswire last month

SER
+1.27%
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to in

GlobeNewswire 2 months ago

SER
+1.27%
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3:00 p.m. PDT. A live webcast of the presentation will be accessible to registered attendees at this link. An arch

GlobeNewswire 2 months ago

SER
+1.27%
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights. "We are encouraged by the progress we’ve made this year. Our partnership with Enable Injections’ wearable technology, combined with our POZ optimization technology,

GlobeNewswire 2 months ago

SER
+1.27%
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will

GlobeNewswire 2 months ago

SER
+1.27%
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages

GlobeNewswire 3 months ago

SER
+1.27%
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a P

GlobeNewswire 4 months ago

SER
+1.27%
Serina Therapeutics Announces Sale of UniverXome Subsidiary

- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-

GlobeNewswire 4 months ago

SER
+1.27%
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen’s financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and deliv

GlobeNewswire 4 months ago

SER
+1.27%
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics, Inc. Tribe Public’s Webinar Event Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson’s patientsDiscussion of the Serina IND candidate’s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- S

GlobeNewswire 5 months ago

SER
+1.27%
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immun

GlobeNewswire 6 months ago

SER
+1.27%
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half

GlobeNewswire 6 months ago

SER
+1.27%
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building on its colla

GlobeNewswire 6 months ago

SER
+1.27%
Serina Therapeutics to Present at the 14th Annual Injectables Summit

HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 14th Annual Injectables Summit in Boston, MA. The joint presentation, with Enable Injections’ Chief Commercial Officer Matthew Huddleston, is entitled “Patient-en

GlobeNewswire 8 months ago

SER
+1.27%
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET. A live webcast of the presentation can be accessed from the Investor section of Serina’s website,

GlobeNewswire 9 months ago

SER
+1.27%

Performance Overview

Return	SER	S&P 500 (^GSPC)
YTD	+19.76%	+1.62%
1-Year	-37.82%	+10.00%
3-Year	-76.99%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Serina Therapeutics, Inc. (SER)

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at the 14th Annual Injectables Summit

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Performance Overview